The EPS projection of Epizyme, Inc. (NASDAQ:EPZM) for period quarter completed 2016-12-31 is $-0.6.
The EPS estimates given a week and 30-days ago were $-0.6 and $-0.6 correspondingly. This number 60 and 90 days before was $-0.6 and $-0.6 respectively. However, over last week ago, the change in EPS estimate is -0.08%.
For the quarter completed 2 mean estimate is $-0.6 based on 5 EPS estimations. As on 2016-08-08 estimated EPS stood at $-0.49 showing surprise of $0.01, or 2%. Following the disclosed forecasts, the standard deviation is $0.06.
The upgrade in EPS revisions were 0 a week earlier against negative revisions of 0. In last 1- month and 60-days, the upgrade in EPS revisions were 0 and 0 correspondingly, whereas for a quarter and 120-days earlier, it was 3 and 3 in that sequence.
The negative revisions of earnings per-share in the last 1-month and 60-days were 0 and 0 in that order. However, a quarter and 120-days earlier, this count was 1 and 1 correspondingly.
EPS revisions downgrade and upgrade in the last 18 days were 1 and 3, correspondingly.
Quarterly Sales Estimates
The arithmetic mean of apparent annual sales of Epizyme, Inc. (NASDAQ:EPZM) is $0.643 and the median is $0.5. The estimate is stated by 4 analysts for the fiscal 2016.
The highest yearly projection is $1.1 and lowest sales mark is $0.473. This results a standard deviation of $0.304.
Almost 4 have revised sales target positively in the past week and 4 have downgraded forecasts. Depending on the stated estimates, the calculated change in target against the past week is 0%.
Nearly 4 revised sales projections positively over the past month and 4 have downgraded forecasts. It leads to a mean estimate deviation of 0%.
Just about 4 have revised sales forecast positively over the quarter and 4 have downgraded forecasts, giving a deviation of -0.771%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...